Abstract

To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors (p = 0.001 and p < 0.001, respectively). Receipt of chemotherapy was associated with improved breast cancer-specific survival (BCSS, adjusted hazard ratio = 0.70; p = 0.006), particularly in patients with T1c tumors (5-year BCSS 94.5% vs. 91.2%).

Details

Title
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer
Author
Tarantino, Paolo 1   VIAFID ORCID Logo  ; Leone, Julieta 2 ; Vallejo, Carlos T. 2 ; Freedman, Rachel A. 3 ; Waks, Adrienne G. 3 ; Martínez-Sáez, Olga 4 ; Garrido-Castro, Ana 3   VIAFID ORCID Logo  ; Lynce, Filipa 3   VIAFID ORCID Logo  ; Tayob, Nabihah 5 ; Lin, Nancy U. 3 ; Tolaney, Sara M. 3   VIAFID ORCID Logo  ; Leone, Jose P. 3   VIAFID ORCID Logo 

1  Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); University of Milan, Department of Oncology and Onco-Hematology, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822) 
2  Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina (GRID:grid.4708.b) 
3  Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
4  Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Brigham Cancer Center, Breast Oncology Program, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896); Hospital Clinic of Barcelona, Medical Oncology Department, Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413); August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Translational Genomics and Targeted Therapeutics in Solid Tumors, Barcelona, Spain (GRID:grid.10403.36) (ISNI:0000000091771775) 
5  Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
Pages
26
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23744677
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41523-024-00634-6
ProQuest document ID
3032863055
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.